Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GnRH Antagonist for Severe Early OHSS
NCT02392520Unknown
- Sponsor
- Eugonia
- Start
- May 2015
- Primary completion
- Mar 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cetrorelix in ovarian hyperstimulation syndrome (OHSS) (2 arms), sponsored by Eugonia. Primary endpoint: Time to severe OHSS regression. Status: unknown.
02
Drugs
cetrorelix
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on NCT02392520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392520.